

NAVETCO CENTRAL VETERINARY SOCIALIST REPUBLIC OF VIETNAM
MEDICINE JOINT STOCK COMPANY Independence – Freedom- Happiness

No: 40 /NVC

TP HCM, January 17, 2025

**Re : Explanation of profit difference in financial,
Statements for Q4/2024 compared to Q4/2023**

**TO: - STATE SECURITIES COMMISSION;
- HANOI STOCK EXCHANGE**

Implementing the Circular No. 96/2020/TT-BTC date November 16, 2020 of the Ministry of Finance on guiding the disclosure of information on the stock market. Navetco central veterinary medicine joint stock company explanation of profit difference in financial statements for Q4/2024 compared to Q4/2023:

STT	Items	Quarter IV 2023	Quarter IV 2024	Balance (2024-2023)
1	Net revenue	133.598.070.138	124.179.066.401	(9.419.003.737)
2	Accounting profit after tax	9.147.116.128	(48.169.664.782)	(57.316.780.910)

Reason:

- The fourth quarter of 2024 continues to be a difficult time for the economy in general. The impact of natural disasters, storms and floods leads to unstable output factors, and wars between countries cause the export market to shrink, leading to a significant decrease in net revenue compared to the same period.

- Profit after tax in the fourth quarter of 2024 decreased due to the company recording compensation and support expenses for the vaccine incident in Lam Dong. This is an unexpected incident that greatly affected the company's business operations in the fourth quarter of 2024.

Navetco central veterinary medicine joint stock company would like to explain to the State Securities Commission, Hanoi Stock Exchange and shareholders of the company.

Sincelery thanks ./.

Recipients: - As above
- Archive: Office, Finance

GENERAL DIRECTOR
CỔ PHẦN
THUỐC THỦ Y
TRUNG ƯƠNG
NAVETCO
QUẬN 1-T.PHỐ CHÍ MINH
NGUYỄN THỊ KIM LAN